<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186770</url>
  </required_header>
  <id_info>
    <org_study_id>MNTX 3201</org_study_id>
    <nct_id>NCT01186770</nct_id>
  </id_info>
  <brief_title>A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Progenics Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MNTX 3201 is a Phase 3, international, multicenter, randomized, double-blind,
      placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral MNTX for
      the treatment of opioid induced constipation in participants with chronic, non-malignant
      pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2010</start_date>
  <completion_date type="Actual">September 8, 2011</completion_date>
  <primary_completion_date type="Actual">September 8, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Percentage of Dosing Days That Resulted in Rescue-Free Bowel Movements (RFBMs) Within 4 Hours of Dosing During Weeks 1 to 4</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>RFBM was defined as a bowel movement without laxative use within 24 hours prior to bowel movement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Responded (Responder) to Study Drug During Weeks 1 to 4</measure>
    <time_frame>Weeks 1 to 4</time_frame>
    <description>A responder was defined as at least 3 RFBMs/week, with an increase of at least 1 RFBM/week over baseline, for at least 3 out of the first 4 weeks of the treatment period. Weekly number of RFBMs were calculated as follows: 7 * total number of RFBMs in a week/all non-missing assessment days in the given week. Weekly number of RFBMs was set to missing for any week when a participant completed less than (&lt;) 4 diary days in a week. A RFBM was a bowel movement without laxative use within 24 hrs prior to the bowel movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weekly Number of RFBMs From Baseline Over the Entire First 4 Weeks (28 Days) of Dosing</measure>
    <time_frame>Baseline, Weeks 1 to 4</time_frame>
    <description>Weekly number of RFBMs were calculated as follows: 7 * total number of RFBMs in a week/all non-missing assessment days in the given week. Weekly number of RFBMs was set to missing for any week when a participant completed less than (&lt;) 4 diary days in a week. A RFBM was a bowel movement without laxative use within 24 hrs prior to the bowel movement.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">804</enrollment>
  <condition>Opioid-Induced Constipation</condition>
  <arm_group>
    <arm_group_label>MNTX 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MNTX 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MNTX 450 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone</intervention_name>
    <description>Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.</description>
    <arm_group_label>MNTX 150 mg</arm_group_label>
    <arm_group_label>MNTX 300 mg</arm_group_label>
    <arm_group_label>MNTX 450 mg</arm_group_label>
    <other_name>Relistor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.</description>
    <arm_group_label>MNTX 150 mg</arm_group_label>
    <arm_group_label>MNTX 300 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. History of chronic non-malignant pain (originating from a non-malignant source) with
             condition(s) underlying the chronic pain of greater than or equal to (≥) 2 months'
             duration before the screening visit.

          2. Taking oral, transdermal, intravenous (IV), or subcutaneous (SC) opioids for chronic
             non-malignant pain for ≥1 month.

          3. No known history of chronic constipation prior to the initiation of opioid therapy.

          4. Currently taking laxative therapy for ≥30 days and willing to discontinue all laxative
             therapy at the start of screening period and use only study-permitted rescue laxatives
             throughout the screening and double-blind treatment periods..

        Key Exclusion Criteria:

          1. Prior treatment with oral MNTX.

          2. Prior treatment with SC MNTX within 30 days of screening.

          3. Women who are pregnant, breastfeeding, or plan to become pregnant during the study.

          4. Fecal incontinence, rectal prolapse, fecal ostomy or other clinically significant
             gastrointestinal disorders such as inflammatory bowel disease or clinically
             significant irritable bowel syndrome that would have made bowel movement assessment
             inaccurate.

          5. Current treatment with partial opioid agonists (for example; buprenorphine) or
             combination agonists/antagonists.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Mathew</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA, Intl.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <results_first_submitted>February 7, 2018</results_first_submitted>
  <results_first_submitted_qc>September 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of Opioid-Induced Constipation in Participants with Chronic, Non-Malignant Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylnaltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 804 participants met inclusion/exclusion criteria and randomized in 1:1:1:1 ratio to either MNTX 150 mg, MNTX 300 mg, MNTX 450 mg, or placebo treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MNTX 150 mg</title>
          <description>Participants received methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks).</description>
        </group>
        <group group_id="P2">
          <title>MNTX 300 mg</title>
          <description>Participants received MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
        </group>
        <group group_id="P3">
          <title>MNTX 450 mg</title>
          <description>Participants received MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participants received 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="200"/>
                <participants group_id="P4" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat (ITT Population)</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="200"/>
                <participants group_id="P4" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="148"/>
                <participants group_id="P4" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligibility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient response to treatment</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population included all randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>MNTX 150 mg</title>
          <description>Participants received MNTX 150 mg (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
        </group>
        <group group_id="B2">
          <title>MNTX 300 mg</title>
          <description>Participants received MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
        </group>
        <group group_id="B3">
          <title>MNTX 450 mg</title>
          <description>Participants received MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants received 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="200"/>
            <count group_id="B4" value="201"/>
            <count group_id="B5" value="803"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="179"/>
                    <measurement group_id="B5" value="727"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="10.32"/>
                    <measurement group_id="B2" value="51.5" spread="10.54"/>
                    <measurement group_id="B3" value="51.4" spread="10.50"/>
                    <measurement group_id="B4" value="52.6" spread="10.33"/>
                    <measurement group_id="B5" value="51.6" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="130"/>
                    <measurement group_id="B5" value="505"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary pain condition requiring opioid medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="145"/>
                    <measurement group_id="B5" value="548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint/extremity pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic/neuropathic pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibromyalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other pain condition requiring opioids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Percentage of Dosing Days That Resulted in Rescue-Free Bowel Movements (RFBMs) Within 4 Hours of Dosing During Weeks 1 to 4</title>
        <description>RFBM was defined as a bowel movement without laxative use within 24 hours prior to bowel movement.</description>
        <time_frame>Weeks 1 to 4</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MNTX 150 mg</title>
            <description>Participants received MNTX 150 mg (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
          </group>
          <group group_id="O2">
            <title>MNTX 300 mg</title>
            <description>Participants received MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
          </group>
          <group group_id="O3">
            <title>MNTX 450 mg</title>
            <description>Participants received MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Percentage of Dosing Days That Resulted in Rescue-Free Bowel Movements (RFBMs) Within 4 Hours of Dosing During Weeks 1 to 4</title>
          <description>RFBM was defined as a bowel movement without laxative use within 24 hours prior to bowel movement.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.05" spread="20.116"/>
                    <measurement group_id="O2" value="24.64" spread="21.311"/>
                    <measurement group_id="O3" value="27.40" spread="23.453"/>
                    <measurement group_id="O4" value="18.18" spread="16.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using analysis of covariance (ANCOVA) with treatment as effect and analysis region as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1692</p_value>
            <p_value_desc>Threshold for significance at 0.0167 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>2.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>6.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using ANCOVA with treatment as effect and analysis region as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0016</p_value>
            <p_value_desc>Threshold for significance at 0.0167 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>6.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.47</ci_lower_limit>
            <ci_upper_limit>10.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using ANCOVA with treatment as effect and analysis region as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Threshold for significance at 0.0167 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>9.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.09</ci_lower_limit>
            <ci_upper_limit>13.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Responded (Responder) to Study Drug During Weeks 1 to 4</title>
        <description>A responder was defined as at least 3 RFBMs/week, with an increase of at least 1 RFBM/week over baseline, for at least 3 out of the first 4 weeks of the treatment period. Weekly number of RFBMs were calculated as follows: 7 * total number of RFBMs in a week/all non-missing assessment days in the given week. Weekly number of RFBMs was set to missing for any week when a participant completed less than (&lt;) 4 diary days in a week. A RFBM was a bowel movement without laxative use within 24 hrs prior to the bowel movement.</description>
        <time_frame>Weeks 1 to 4</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug. Missing data was imputed using last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>MNTX 150 mg</title>
            <description>Participants received MNTX 150 mg (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
          </group>
          <group group_id="O2">
            <title>MNTX 300 mg</title>
            <description>Participants received MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
          </group>
          <group group_id="O3">
            <title>MNTX 450 mg</title>
            <description>Participants received MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Responded (Responder) to Study Drug During Weeks 1 to 4</title>
          <description>A responder was defined as at least 3 RFBMs/week, with an increase of at least 1 RFBM/week over baseline, for at least 3 out of the first 4 weeks of the treatment period. Weekly number of RFBMs were calculated as follows: 7 * total number of RFBMs in a week/all non-missing assessment days in the given week. Weekly number of RFBMs was set to missing for any week when a participant completed less than (&lt;) 4 diary days in a week. A RFBM was a bowel movement without laxative use within 24 hrs prior to the bowel movement.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug. Missing data was imputed using last observation carried forward (LOCF) method.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3"/>
                    <measurement group_id="O2" value="51.7"/>
                    <measurement group_id="O3" value="54.5"/>
                    <measurement group_id="O4" value="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using logistic regression model with treatment as effect and analysis region as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3076</p_value>
            <p_value_desc>Threshold for significance at 0.0167 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using logistic regression model with treatment as effect and analysis region as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0339</p_value>
            <p_value_desc>Threshold for significance at 0.0167 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using logistic regression model with treatment as effect and analysis region as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0043</p_value>
            <p_value_desc>Threshold for significance at 0.0167 level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weekly Number of RFBMs From Baseline Over the Entire First 4 Weeks (28 Days) of Dosing</title>
        <description>Weekly number of RFBMs were calculated as follows: 7 * total number of RFBMs in a week/all non-missing assessment days in the given week. Weekly number of RFBMs was set to missing for any week when a participant completed less than (&lt;) 4 diary days in a week. A RFBM was a bowel movement without laxative use within 24 hrs prior to the bowel movement.</description>
        <time_frame>Baseline, Weeks 1 to 4</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug. Missing data was imputed using LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>MNTX 150 mg</title>
            <description>Participants received MNTX 150 mg (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
          </group>
          <group group_id="O2">
            <title>MNTX 300 mg</title>
            <description>Participants received MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
          </group>
          <group group_id="O3">
            <title>MNTX 450 mg</title>
            <description>Participants received MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weekly Number of RFBMs From Baseline Over the Entire First 4 Weeks (28 Days) of Dosing</title>
          <description>Weekly number of RFBMs were calculated as follows: 7 * total number of RFBMs in a week/all non-missing assessment days in the given week. Weekly number of RFBMs was set to missing for any week when a participant completed less than (&lt;) 4 diary days in a week. A RFBM was a bowel movement without laxative use within 24 hrs prior to the bowel movement.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug. Missing data was imputed using LOCF method.</population>
          <units>RFBMs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="200"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.911"/>
                    <measurement group_id="O2" value="1.35" spread="0.891"/>
                    <measurement group_id="O3" value="1.37" spread="0.789"/>
                    <measurement group_id="O4" value="1.49" spread="1.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change during Weeks 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="2.139"/>
                    <measurement group_id="O2" value="2.43" spread="2.616"/>
                    <measurement group_id="O3" value="2.44" spread="2.515"/>
                    <measurement group_id="O4" value="1.87" spread="2.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using ANCOVA model with treatment as effect and analysis region and baseline as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6920</p_value>
            <p_value_desc>Threshold for significance at 0.0167 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using ANCOVA model with treatment as effect and analysis region and baseline as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0274</p_value>
            <p_value_desc>Threshold for significance at 0.0167 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using ANCOVA model with treatment as effect and analysis region and baseline as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0237</p_value>
            <p_value_desc>Threshold for significance at 0.0167 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (Day 1) up to Day 98</time_frame>
      <desc>Adverse events were collected by non-systematic (participant reports) and systematic methods (investigator examinations and lab tests). For both adverse events tables, a participant reporting more than one adverse event for a particular MedDRA preferred term or system organ class was counted only once for that MedDRA preferred term or system organ class.</desc>
      <group_list>
        <group group_id="E1">
          <title>MNTX 150 mg</title>
          <description>Participants received MNTX 150 mg (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
        </group>
        <group group_id="E2">
          <title>MNTX 300 mg</title>
          <description>Participants received MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
        </group>
        <group group_id="E3">
          <title>MNTX 450 mg</title>
          <description>Participants received MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participants received 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Myositis ossificans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Please contact Sponsor directly for additional information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>Bausch Health Americas, Inc</organization>
      <email>Lindsey.Mathew@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

